Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
Shenxia Xie,1,2,* Xiaoqiong Hou,1,3,* Wei Yang,1,3,* Wei Shi,1,3 Xiaomei Yang,1,3 Siliang Duan,3 Fengzhen Mo,3 Aiqun Liu,3 Wu Wang,1,4 Xiaoling Lu1,3,5 1School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 2Pharmaceutical C...
Enregistré dans:
Auteurs principaux: | Xie S, Hou X, Yang W, Shi W, Yang X, Duan S, Mo F, Liu A, Wang W, Lu X |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/48b255791dcb4f11a4760fe5dd34419b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus
par: Betül Ekiz-Bilir, et autres
Publié: (2018) -
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
par: Zhang L, et autres
Publié: (2021) -
Bioinformational analysis of Yersinia pseudotuberculosis IP32953 CRISPR/cas system
par: N. P. Peretolchina, et autres
Publié: (2016) -
Immunotherapeutic Advances for NSCLC
par: Massafra M, et autres
Publié: (2021) -
The Usefulness of Urinary Periostin, Cytokeratin-18, and Endoglin for Diagnosing Renal Fibrosis in Children with Congenital Obstructive Nephropathy
par: Agnieszka Turczyn, et autres
Publié: (2021)